Acumen Pharmaceuticals, Inc. (ABOS) Stock Analysis
Acumen is a deeply discounted, high-risk Alzheimer’s catalyst play where late-2026 Phase 2 data could either validate a best-in-class oligomer antibody platform or erase most remaining equity value.
Overview
Acumen Pharmaceuticals is a binary, catalyst-driven Alzheimer’s biotech centered on sabirnetug, an oligomer-selective antibody designed to improve on lecanemab and donanemab by targeting toxic soluble amyloid species with potentially lower ARIA risk. The key event is late-2026 Phase 2 ALTITUDE-AD topline data. With $128.4M cash funding operations into early 2027 and an EV near $93M, the market appears to discount high failure odds despite unanimous Strong Buy analyst sentiment and major upside if clinical efficacy is validated.